1
|
Montembeault M, Sayah S, Rinaldi D, Le Toullec B, Bertrand A, Funkiewiez A, Saracino D, Camuzat A, Couratier P, Chouly M, Hannequin D, Aubier-Girard C, Pasquier F, Delbeuck X, Colliot O, Batrancourt B, Azuar C, Lévy R, Dubois B, Le Ber I, Migliaccio R. Cognitive inhibition impairments in presymptomatic C9orf72 carriers. J Neurol Neurosurg Psychiatry 2020; 91:366-372. [PMID: 32054668 DOI: 10.1136/jnnp-2019-322242] [Citation(s) in RCA: 14] [Impact Index Per Article: 3.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 10/17/2019] [Revised: 01/13/2020] [Accepted: 01/15/2020] [Indexed: 12/11/2022]
Abstract
OBJECTIVE To investigate cognitive inhibition in presymptomatic C9orf72 mutation carriers (C9+) and its associated neuroanatomical correlates. METHODS Thirty-eight presymptomatic C9orf72 mutation carriers (C9+, mean age 38.2±8.0 years) and 22 C9- controls from the PREV-DEMALS cohort were included in this study. They underwent a cognitive inhibition assessment with the Hayling Sentence Completion Test (HSCT; time to completion (part B-part A); error score in part B) as well as a 3D MRI. RESULTS C9+ individuals younger than 40 years had higher error scores (part B) but equivalent HSCT time to completion (part B-part A) compared to C9- individuals. C9+ individuals older than 40 years had both higher error scores and longer time to completion. HSCT time to completion significantly predicted the proximity to estimated clinical conversion from presymptomatic to symptomatic phase in C9+ individuals (based on the average age at onset of affected relatives in the family). Anatomically, we found that HSCT time to completion was associated with the integrity of the cerebellum. CONCLUSION The HSCT represents a good marker of cognitive inhibition impairments in C9+ and of proximity to clinical conversion. This study also highlights the key role of the cerebellum in cognitive inhibition.
Collapse
Affiliation(s)
- Maxime Montembeault
- Inserm U1127, Institut du Cerveau, Hôpital Pitié-Salpêtrière, Paris, France.,Sorbonne University, Paris, France.,FrontLab, Paris, France.,Department of Neurology, University of California San Francisco, Memory and Aging Center, San Francisco, California, USA
| | - Sabrina Sayah
- Inserm U1127, Institut du Cerveau, Hôpital Pitié-Salpêtrière, Paris, France
| | - Daisy Rinaldi
- Inserm U1127, Institut du Cerveau, Hôpital Pitié-Salpêtrière, Paris, France.,Reference Centre for Rare of Early Onset Dementias, Hôpital Pitié-Salpêtrière, Assistance Publique-Hôpitaux de Paris, Paris, France
| | - Benjamin Le Toullec
- Inserm U1127, Institut du Cerveau, Hôpital Pitié-Salpêtrière, Paris, France.,Reference Centre for Rare of Early Onset Dementias, Hôpital Pitié-Salpêtrière, Assistance Publique-Hôpitaux de Paris, Paris, France
| | - Anne Bertrand
- Sorbonne University, Paris, France.,Sorbonne Universités, Université Pierre et Marie Curie Paris 06, Institut National de la Santé et de la Recherche Médicale, Centre National de la Recherche Scientifique, Institut du Cerveau et la Moelle Épinière, FrontLAB, Hôpital Pitié-Salpêtrière, Assistance Publique-Hôpitaux de Paris, Paris, France.,Aramis Project Team, Inria Research Center of Paris, Paris, France
| | - Aurélie Funkiewiez
- Reference Centre for Rare of Early Onset Dementias, Hôpital Pitié-Salpêtrière, Assistance Publique-Hôpitaux de Paris, Paris, France.,Institute of Memory and Alzheimer's Disease, Centre of Excellence of Neurodegenerative Disease, Department of Neurology, Hôpital Pitié-Salpêtrière, Assistance Publique-Hôpitaux de Paris, Paris, France
| | - Dario Saracino
- Inserm U1127, Institut du Cerveau, Hôpital Pitié-Salpêtrière, Paris, France.,Reference Centre for Rare of Early Onset Dementias, Hôpital Pitié-Salpêtrière, Assistance Publique-Hôpitaux de Paris, Paris, France.,Aramis Project Team, Inria Research Center of Paris, Paris, France
| | - Agnès Camuzat
- Inserm U1127, Institut du Cerveau, Hôpital Pitié-Salpêtrière, Paris, France
| | - Philippe Couratier
- Centre de Référence SLA et autres maladies du motoneurone, Centre Hospitalier Universitaire de Limoges, Limoges, France.,Centre de Compétence Démences Rares, Centre Hospitalier Universitaire de Limoges, Limoges, France
| | - Marianne Chouly
- Centre de Référence SLA et autres maladies du motoneurone, Centre Hospitalier Universitaire de Limoges, Limoges, France.,Centre de Compétence Démences Rares, Centre Hospitalier Universitaire de Limoges, Limoges, France
| | - Didier Hannequin
- Centre National de Référence pour les Malades Alzheimer Jeunes, Centre Hospitalier Universitaire de Rouen, INSERM 1245, Rouen, France.,Department of Neurology, Centre Hospitalier Universitaire de Rouen, Rouen, France
| | - Carole Aubier-Girard
- Centre National de Référence pour les Malades Alzheimer Jeunes, Centre Hospitalier Universitaire de Rouen, INSERM 1245, Rouen, France.,Department of Neurology, Centre Hospitalier Universitaire de Rouen, Rouen, France
| | - Florence Pasquier
- Université de Lille, INSERM U1171, Centre de la mémoire (CMRR), Centre national de référence pour les malades Alzheimer jeunes (CNRMAJ), CHU Lille, Development of Innovative Strategies for a Transdisciplinary approach to ALZheimer's disease (DistAlz), Lille, France
| | - Xavier Delbeuck
- Université de Lille, INSERM U1171, Centre de la mémoire (CMRR), Centre national de référence pour les malades Alzheimer jeunes (CNRMAJ), CHU Lille, Development of Innovative Strategies for a Transdisciplinary approach to ALZheimer's disease (DistAlz), Lille, France
| | - Olivier Colliot
- Inserm U1127, Institut du Cerveau, Hôpital Pitié-Salpêtrière, Paris, France.,Aramis Project Team, Inria Research Center of Paris, Paris, France
| | - Bénédicte Batrancourt
- Inserm U1127, Institut du Cerveau, Hôpital Pitié-Salpêtrière, Paris, France.,Sorbonne University, Paris, France.,FrontLab, Paris, France
| | - Carole Azuar
- Inserm U1127, Institut du Cerveau, Hôpital Pitié-Salpêtrière, Paris, France.,FrontLab, Paris, France.,Reference Centre for Rare of Early Onset Dementias, Hôpital Pitié-Salpêtrière, Assistance Publique-Hôpitaux de Paris, Paris, France
| | - Richard Lévy
- Inserm U1127, Institut du Cerveau, Hôpital Pitié-Salpêtrière, Paris, France.,Sorbonne University, Paris, France.,FrontLab, Paris, France.,Reference Centre for Rare of Early Onset Dementias, Hôpital Pitié-Salpêtrière, Assistance Publique-Hôpitaux de Paris, Paris, France
| | - Bruno Dubois
- Inserm U1127, Institut du Cerveau, Hôpital Pitié-Salpêtrière, Paris, France.,Sorbonne University, Paris, France.,Reference Centre for Rare of Early Onset Dementias, Hôpital Pitié-Salpêtrière, Assistance Publique-Hôpitaux de Paris, Paris, France
| | - Isabelle Le Ber
- Inserm U1127, Institut du Cerveau, Hôpital Pitié-Salpêtrière, Paris, France.,Sorbonne University, Paris, France.,FrontLab, Paris, France.,Reference Centre for Rare of Early Onset Dementias, Hôpital Pitié-Salpêtrière, Assistance Publique-Hôpitaux de Paris, Paris, France
| | - Raffaella Migliaccio
- Inserm U1127, Institut du Cerveau, Hôpital Pitié-Salpêtrière, Paris, France .,Sorbonne University, Paris, France.,FrontLab, Paris, France.,Reference Centre for Rare of Early Onset Dementias, Hôpital Pitié-Salpêtrière, Assistance Publique-Hôpitaux de Paris, Paris, France
| | | |
Collapse
|
3
|
Lefaucheur R, Lebas A, Gérardin E, Grangeon L, Ozkul-Wermester O, Aubier-Girard C, Martinaud O, Maltête D. Leucoencephalopathy following abuse of sniffed heroin. J Clin Neurosci 2016; 35:70-72. [PMID: 27742371 DOI: 10.1016/j.jocn.2016.09.023] [Citation(s) in RCA: 11] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/14/2016] [Accepted: 09/26/2016] [Indexed: 11/25/2022]
Abstract
A 29-year-old man was admitted for acute cognitive impairment. Three weeks earlier, he had been admitted for coma due to sniffed heroin abuse responsive to naloxone infusion. At admission, the patient presented with apraxia, severe memory impairment and anosognosia. Brain MRI revealed symmetric hyperintensities of supratentorial white matter, sparing brainstem and cerebellum, on FLAIR and B1000 sequences. Four months later, repeated neuropsychological assessment revealed dramatic improvement of global cognitive functions. Toxic leucoencephalopathy excluding the cerebellum and brainstem is a rare complication of heroin abuse, and seems to concern especially patients that use heroin by sniff or injection. In these patients, cognitive troubles are predominant, prognosis seems better and infratentorial brain structures can be spared. In conclusion, our observation emphasizes that heroin-induced encephalopathy can have a favourable outcome and that imaging and clinical patterns can indicate the mode of drug administration.
Collapse
Affiliation(s)
- Romain Lefaucheur
- Department of Neurology, Rouen University Hospital and University of Rouen, France.
| | - Axel Lebas
- Department of Neurophysiology, Rouen University Hospital and University of Rouen, France
| | - Emmanuel Gérardin
- Department of Radiology, Rouen University Hospital and University of Rouen, France
| | - Lou Grangeon
- Department of Neurology, Rouen University Hospital and University of Rouen, France
| | | | - Carole Aubier-Girard
- Department of Neurology, Rouen University Hospital and University of Rouen, France
| | - Olivier Martinaud
- Department of Neurology, Rouen University Hospital and University of Rouen, France
| | - David Maltête
- Department of Neurology, Rouen University Hospital and University of Rouen, France; INSERM Unit 1073, Rouen, France
| |
Collapse
|